This article was downloaded by:


On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <a href="http://www.informaworld.com/smpp/title~content=t713597286">http://www.informaworld.com/smpp/title~content=t713597286</a>

## Novel Short Oligonucleotide Conjugates as Inhibitors of Human Telomerase

Krisztina Pongracz<sup>ab</sup>; Shihong Li<sup>a</sup>; Brittney-Shea Herbert<sup>c</sup>; Ronald Pruzan<sup>a</sup>; Ellen Wunder<sup>a</sup>; Allison Chin<sup>a</sup>; Mieczysław Piatyszek<sup>a</sup>; Jerry Shay<sup>c</sup>; Sergei M. Gryaznov<sup>a</sup>

<sup>a</sup> Geron Corporation, Menlo Park, California, USA <sup>b</sup> Geron Corporation, Menlo Park, CA, USA <sup>c</sup> Department of Cell Biology, UTSW Medical Center, Dallas, Texas, USA

Online publication date: 09 August 2003

To cite this Article Pongracz, Krisztina , Li, Shihong , Herbert, Brittney-Shea , Pruzan, Ronald , Wunder, Ellen , Chin, Allison , Piatyszek, Mieczysław , Shay, Jerry and Gryaznov, Sergei M.(2003) 'Novel Short Oligonucleotide Conjugates as Inhibitors of Human Telomerase', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 1627-1629

To link to this Article: DOI: 10.1081/NCN-120023085 URL: http://dx.doi.org/10.1081/NCN-120023085

### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS Vol. 22, Nos. 5–8, pp. 1627–1629, 2003

# Novel Short Oligonucleotide Conjugates as Inhibitors of Human Telomerase

Krisztina Pongracz,<sup>1,\*</sup> Shihong Li,<sup>1</sup> Brittney-Shea Herbert,<sup>2</sup> Ronald Pruzan,<sup>1</sup> Ellen Wunder,<sup>1</sup> Allison Chin,<sup>1</sup> Mieczysław Piatyszek,<sup>1</sup> Jerry Shay,<sup>2</sup> and Sergei M. Gryaznov<sup>1</sup>

<sup>1</sup>Geron Corporation, Menlo Park, California, USA <sup>2</sup>Department of Cell Biology, UTSW Medical Center, Dallas, Texas, USA

### **ABSTRACT**

A series of oligonucleotide conjugates were designed and synthesized as novel inhibitors of human telomerase. These compounds contain a relatively short (6–7-mer) oligonucleotide domain, with an  $N3' \rightarrow P5'$  phosphoramidate (np) or thio-phosphoramidate (nps) backbone, targeted to the template region of the RNA component of the enzyme and various pendant groups attached to either their 5'- or preferably to the 3'- termini. The most potent compounds in the series inhibited telomerase with low nM IC50 values in biochemical assays whereas the cognate oligonucleotides without the pendant groups were significantly less active having IC50 values 100-1000-fold higher.

Key Words: Telomerase inhibitors; Oligonucleotide thio-phosphoramidates.

1627

DOI: 10.1081/NCN-120023085 Copyright © 2003 by Marcel Dekker, Inc. 1525-7770 (Print); 1532-2335 (Online) www.dekker.com



<sup>\*</sup>Correspondence: Krisztina Pongracz, Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA; Fax: +1650 473 7750; E-mail: kpongracz@geron.com.

Downloaded At: 11:22 26 January 2011

#### RESULTS AND DISCUSSION

Telomerase is a specialized reverse transcriptase whose main function is telomere maintenance. The vast majority of tumor cells have been shown to express telomerase and its inhibition can induce cell senescence, cell crisis and apoptosis. [1] The RNA component (hTR) of human telomerase can be targeted with oligonucleotides comprising various sugar-phosphate backbones. We have previously shown that 11-15mer oligonucleotides,  $N3' \rightarrow P5'$  phosphoramidate (np) and *thio*-phosphoramidate (nps), targeted to template and non-template regions of hTR, have good inhibitory activity in both biochemical assays and in cells. [2] Here we report the synthesis and anti-telomerase activity of relatively short (6-7-mer) oligonucleotide phosphoramidate conjugates, containing dyes or polyaromatic groups. The IC<sub>50</sub> values for these compounds with sequences TTAGGG, GGGTTAG or GTTAGG and various pendant groups are shown in Table 1. Oligonucleotide conjugates with thio-phosphoramidate backbones (nps) exhibit better inhibitory activity than their phosphoramidate (np) counterparts. Comparison of the various dyes shows that the presence of hydroxyl groups in their aromatic systems (fluorescein vs. TAMRA) improves their inhibitory activity, while introduction of a 3'- flexable linker between the dye and the oligonucleotide results in decreased activity. Conjugates containing the DNA/RNA intercalator acridine are inferior to the dye containing molecules. Lastly, the 3'-trityl conjugates of sequence TTAGGG showed better inhibitory activity than those of GGGTTAG.

In brief summary, telomerase inhibitory activity of short oligonucleotide conjugates is determined by the oligonucleotide sequence, their sugar-phosphate backbone (np vs. nps backbone), the attachment site (5' vs. 3'), the type of the linker

**Table 1.** Structures and IC<sub>50</sub> values in biochemical assays for oligonucleotide N3'  $\rightarrow$  P5' phosphoramidate (np) and *thio*-phosphoramidate (nps) conjugates.

Compound	$IC_{50}$ ( $\mu mM$ ), np	$IC_{50}(\mu mM)$ , nps
TTAGGG	10	1.36
TTAGGG-fluorescein-3'	0.055	0.015
TTAGGG-L-fluorescein-3'	1.9	0.017
TTAGGG-(L-fluorescein) <sub>2</sub> -3'	0.023	n.d.
TTAGGG-TAMRA-3'	0.51	0.044
TTAGGG-L-TAMRA-3'	15	n.d
TTAGGG-Oregon Green-3'	0.046	n.d.
TTAGGG-trityl-3'	0.011	0.005
TTAGGG-pyrene-3'	0.856	n.d.
5'-acridine-TTAGGG	0.593	0.085
GGGTTAG	0.48	0.008
GGGTTAG-fluorescein-3'	0.153	0.004
GGGTTAG-L-fluorescein-3'	0.059	0.004
GGGTTAG-trityl-3'	0.684	0.053
GTTAGG	0.644	0.205
GTTAGG-fluorescein-3'	0.259	0.040
GTTAGG-L-fluorescein-3'	1.66	0.014

(rigid thio-urea vs. relatively flexible hydrocarbon chain), and the structure of the pendant group. While the parent short oligonucleotides do not bind very strongly to the template region of hTR, their conjugation with the pendant groups may provide for additional stabilizing interactions with the telomerase protein component (hTERT) resulting in significant (by up to  $\sim 1000$  fold) increases in their inhibitory activity.

The dyes were attached either via a thio-urea group directly to the terminal 3'-amino group of the oligonucleotides (–), or through  $(CH_2)_5$ - $(CH_2)_6$  containing phosphoramidate linkers (L).

Cellular activity was assessed for a selected group of *thio*-phosphoramidate conjugates using a cell-based telomerase detection TRAP (telomere repeat amplification protocol) assay in several cancer cell lines. The telomerase inhibition activity was found to be in the low  $\mu$ M range. Experiments using *thio*-TTAGGG-*fluorescein* have also demonstrated cellular uptake of this compound in A431, HME50-5E and HT-3 cells, and in the presence of oligofectamine, efficient nuclear delivery was detected.

#### REFERENCES

- 1. Hahn, W.C.; Stewart, S.A.; Brooks, M.W.; York, S.G.; Eaton, E.; Kurachi, A.; Bejersbergen, R.L.; Knoll, J.H.; Meyerson, M.; Weinberg, R.A. Inhibition of telomerase limits the growth of human cancer cells. Nature Med. **1999**, *10*, 1164–1170.
- Herbert, B-S.; Pongracz, K.; Shay, J.W.; Gryaznov, S.M. Oligonucleotide N3' → P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 2002, 28, 638 pp.